Department of Medicine & Geriatrics, Tuen Mun Hospital, Tuen Mun, HKSAR, China;
J Gastrointest Oncol. 2013 Jun;4(2):198-202. doi: 10.3978/j.issn.2078-6891.2013.014.
To analyze the clinical characteristics, treatment outcome of patients with gastric extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type (EMZBL-MALT).
Data of 30 patients with gastric EMZBL-MALT diagnosed in Caritas Medical Center between July 1997 and June 2009 were analyzed retrospectively.
The median follow-up time was 6.4 years [interquartile range (IQR) 3.9 to 8.9 years] and the median age at time of diagnosis was 71.5 years (IQR 64 to 81 years). All subjects, with investigations done for disease staging, suffered from localized disease (stage I or II1). Helicobacter infection was identified in 67% of subjects. Twenty Helicobacter-positive subjects received Helicobacter eradication treatment and seven Helicobacter-negative subjects received single-agent chemotherapy (cyclophosphamide), with disease remission rates at 85% and 71% respectively. Only one subject died apparently from disease progression. The 5-year and 10-year overall survival rates were 75% and 62.5% respectively.
Helicobacter eradication and single-agent chemotherapy were effective treatment modalities for early stage gastric EMZBL-MALT with and without Helicobacter infection respectively. Survival was favorable.
分析胃黏膜相关淋巴组织边缘区 B 细胞淋巴瘤（MALT 型）的临床特征和治疗效果。
回顾性分析 1997 年 7 月至 2009 年 6 月在明爱医院诊断的 30 例胃 MALT 边缘区 B 细胞淋巴瘤患者的临床资料。
中位随访时间为 6.4 年（四分位间距 3.9 至 8.9 年），诊断时的中位年龄为 71.5 岁（四分位间距 64 至 81 岁）。所有患者均进行了疾病分期检查，均为局限性疾病（Ⅰ期或Ⅱ期 1 期）。67%的患者存在幽门螺杆菌感染。20 例幽门螺杆菌阳性患者接受了幽门螺杆菌根除治疗，7 例幽门螺杆菌阴性患者接受了单药化疗（环磷酰胺），疾病缓解率分别为 85%和 71%。仅有 1 例患者因疾病进展而死亡。5 年和 10 年总生存率分别为 75%和 62.5%。
对于早期胃 MALT 边缘区 B 细胞淋巴瘤，幽门螺杆菌根除和单药化疗分别是合并或不合并幽门螺杆菌感染患者的有效治疗方法，生存情况良好。
